
|Articles|September 20, 2011
Positive Phase II study results announced
Novagali Pharma has announced positive results from its Phase II trial of the preservative-free cationic emulsion, Catioprost.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: New horizons in research and risk management for ROP
2
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
3
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5













































